Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:07 PM ET
LEXX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.57M
- EPS (TTM)
- -$5.10
- Dividend yield
- None
- 52-week range
- 2.77 – 21.60
- Day range
- 3.12 – 3.90
- Volume / Avg
- 165.21K / 62.36K
- Beta
- —
- Shares outstanding
- 2.11M
52-week range
LEXX stock today
Shares of Lexaria Bioscience (LEXX) are trading lower on Oct 9 at $3.12, a drop of 7.14% or $0.24 per share, versus the S&P 500's 0.57% gain. Volume was 2.6x the average at 165.21K shares, a sign of unusually heavy trading. Shares are 85.6% below their 52-week high of $21.60 and 12.6% above the 52-week low of $2.77, near the bottom of the past year's range.
Lexaria Bioscience has posted a net loss over the last twelve months (EPS of -$5.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lexaria Bioscience
Company profileLexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard C. Christopher
- Headquarters
- Kelowna, BC
- Employees
- 7
- Website
- lexariabioscience.com
Analyst forecast
ForecastConsensus
none
Avg. price target
$82.50+2544.23%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Lexaria Bioscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APUSApimeds Pharmaceuticals US Inc. | 4.53 | -17.79% | $6.84M | vs LEXX |
| XCURExicure Inc. | 1.01 | 0.00% | $6.61M | vs LEXX |
| ENVBEnveric Biosciences Inc. | 1.47 | -3.29% | $6.58M | vs LEXX |
| ALZNAlzamend Neuro Inc. | 1.36 | +1.49% | $6.56M | vs LEXX |
| TRAWTraws Pharma Inc. | 0.4504 | -6.23% | $6.92M | vs LEXX |
| ACXPAcurx Pharmaceuticals Inc. | 1.26 | +0.80% | $7.00M | vs LEXX |
| NRSNNeuroSense Therapeutics Ltd. | 3.80 | +1.60% | $7.21M | vs LEXX |
| SCNXScienture Holdings Inc. | 3.76 | -2.59% | $6.18M | vs LEXX |
Indexes, lists and sector
Lexaria Bioscience stock FAQ
What is Lexaria Bioscience's stock price today?
LEXX last traded at $3.12 as of Oct 9, 2:07 PM EDT, down 7.14% on the day. Prices are delayed at least 15 minutes.
Who is Lexaria Bioscience's CEO?
Mr. Richard C. Christopher is the chief executive officer of Lexaria Bioscience Corp., which has about 7 employees.
What is the LEXX 52-week high?
The 52-week high for LEXX is $21.60 and the 52-week low is $2.77. The stock is currently 85.6% below its high.